Literature DB >> 17982252

Molecular mechanisms of schizophrenia.

Undine E Lang1, Imke Puls, Daniel J Muller, Nathalie Strutz-Seebohm, Jurgen Gallinat.   

Abstract

Schizophrenia is a complex disorder, where family, twin and adoption studies have been demonstrating a high heritability of the disease and that this disease is not simply defined by several major genes but rather evolves from addition or potentiation of a specific cluster of genes, which subsequently determines the genetic vulnerability of an individual. Linkage and association studies suggest that a genetic vulnerablility, is not forcefully leading to the disease since triggering factors and environmental influences, i.e. birth complications, drug abuse, urban background or time of birth have been identified. This has lead to the assumption that schizophrenia is not only a genetically defined static disorder but a dynamic process leading to dysregulation of multiple pathways. There are several different hypothesis based on several facets of the disease, some of them due to the relatively well-known mechanisms of therapeutic agents. The most widely considered neurodevelopmental hypothesis of schizophrenia integrates environmental influences and causative genes. The dopamine hypothesis of schizophrenia is based on the fact that all common treatments involve antidopaminergic mechanisms and genes such as DRD2, DRD3, DARPP-32, BDNF or COMT are closely related to dopaminergic system functioning. The glutamatergic hypothesis of schizophrenia lead recently to a first successful mGlu2/3 receptor agonistic drug and is underpinned by significant findings in genes regulating the glutamatergic system (SLC1A6, SLC1A2 GRIN1, GRIN2A, GRIA1, NRG1, ErbB4, DTNBP1, DAAO, G72/30, GRM3). Correspondingly, GABA has been proposed to modulate the pathophysiology of the disease which is represented by the involvement of genes like GABRA1, GABRP, GABRA6 and Reelin. Moreover, several genes implicating immune, signaling and networking deficits have been reported to be involved in the disease, i.e. DISC1, RGS4, PRODH, DGCR6, ZDHHC8, DGCR2, Akt, CREB, IL-1B, IL-1RN, IL-10, IL-1B. However, molecular findings suggest that a complex interplay between receptors, kinases, proteins and hormones is involved in schizophrenia. In a unifying hypothesis, different cascades merge into another that ultimately lead to the development of symptoms adherent to schizophrenic disorders.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17982252     DOI: 10.1159/000110430

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  82 in total

Review 1.  Significance of SGK1 in the regulation of neuronal function.

Authors:  Florian Lang; Nathalie Strutz-Seebohm; Guiscard Seebohm; Undine E Lang
Journal:  J Physiol       Date:  2010-06-07       Impact factor: 5.182

Review 2.  Brain-derived neurotrophic factor and neuropsychiatric disorders.

Authors:  Anita E Autry; Lisa M Monteggia
Journal:  Pharmacol Rev       Date:  2012-03-08       Impact factor: 25.468

3.  Partial support for ZNF804A genotype-dependent alterations in prefrontal connectivity.

Authors:  Frieder M Paulus; Sören Krach; Johannes Bedenbender; Martin Pyka; Jens Sommer; Axel Krug; Susanne Knake; Markus M Nöthen; Stephanie H Witt; Marcella Rietschel; Tilo Kircher; Andreas Jansen
Journal:  Hum Brain Mapp       Date:  2011-10-31       Impact factor: 5.038

Review 4.  Molecular pathways: dysregulated glutamatergic signaling pathways in cancer.

Authors:  Todd D Prickett; Yardena Samuels
Journal:  Clin Cancer Res       Date:  2012-05-30       Impact factor: 12.531

Review 5.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

6.  Immersion in altered experience: An investigation of the relationship between absorption and psychopathology.

Authors:  Cherise Rosen; Nev Jones; Kayla A Chase; Jennifer K Melbourne; Linda S Grossman; Rajiv P Sharma
Journal:  Conscious Cogn       Date:  2017-02-20

7.  Genetic association analysis of tagging SNPs in alpha4 and beta2 subunits of neuronal nicotinic acetylcholine receptor genes (CHRNA4 and CHRNB2) with schizophrenia in the Japanese population.

Authors:  Taro Kishi; Masashi Ikeda; Tsuyoshi Kitajima; Yoshio Yamanouchi; Yoko Kinoshita; Kunihiro Kawashima; Tomo Okochi; Toshiya Inada; Norio Ozaki; Nakao Iwata
Journal:  J Neural Transm (Vienna)       Date:  2008-09-02       Impact factor: 3.575

Review 8.  Neuregulin-1 signalling and antipsychotic treatment: potential therapeutic targets in a schizophrenia candidate signalling pathway.

Authors:  Chao Deng; Bo Pan; Martin Engel; Xu-Feng Huang
Journal:  Psychopharmacology (Berl)       Date:  2013-02-07       Impact factor: 4.530

9.  Altered social behavior and neuronal development in mice lacking the Uba6-Use1 ubiquitin transfer system.

Authors:  Peter C W Lee; Jean-Cosme Dodart; Liviu Aron; Lydia W Finley; Roderick T Bronson; Marcia C Haigis; Bruce A Yankner; J Wade Harper
Journal:  Mol Cell       Date:  2013-03-14       Impact factor: 17.970

10.  Association between Interleukin 31 Receptor A Gene Polymorphism and Schizophrenia in Korean Population.

Authors:  Ju Yeon Ban; Su Kang Kim; Hak-Jae Kim; Joo-Ho Chung; Tae Kim; Jin Kyung Park; Hyun-Kyung Park; Jong Woo Kim
Journal:  Korean J Physiol Pharmacol       Date:  2008-08-31       Impact factor: 2.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.